The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD)

Publications

Bochtler T, Christopoulos P, Schlamp K, Winkler F, Krämer A

Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum.

Clinical lung cancer 2024 Jan;25;72-76 — 2024 Jan — 72-76

Chen X, Xia D, Jiang X, Cao L, Ryu JH, Hu X

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer.

Frontiers in pharmacology 2022;13;944685 — 2022 — 944685

Kashizaki F, Tanaka A, Sekido Y

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.

Journal of medical case reports 2022 Aug 24;16;316 — 2022 Aug 24 — 316

Hwang A, Iskandar A, Dasanu CA

Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018 Dec 20;;1078155218820580 — 2018 Dec 20 — 1078155218820580

Nitawaki T, Sakata Y, Kawamura K, Ichikado K

Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.

BMC pulmonary medicine 2017 Dec 06;17;173 — 2017 Dec 06 — 173

Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

Clinical lung cancer 2018 03;19;e151-e161 — 2018 03 — e151-e161

Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y

Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.

Investigational new drugs 2015 Oct;33;1148-50 — 2015 Oct — 1148-50

Ikeda S, Yoshioka H, Arita M, Sakai T, Sone N, Nishiyama A, Niwa T, Hotta M, Tanaka T, Ishida T

Interstitial lung disease induced by alectinib (CH5424802/RO5424802).

Japanese journal of clinical oncology 2015 Feb;45;221-4 — 2015 Feb — 221-4